title: Immunohistochemical analysis of desmoid tumours.
abstract: OBJECTIVE
  Although the standard treatment for desmoid tumours is complete surgical resection with wide margins, the optimal adjuvant treatment for recurrent or inoperable disease is unclear, often being based on sporadic immunohistochemical reports with a low number of cases. Therefore, a large immunohistochemical study was performed, to provide a theoretical basis for adjuvant treatment regimens.
  
  
  METHODS
  One hundred and sixteen tissue samples from 80 patients (49 female, 31 male; mean age, 34 years; range, 0-83) with desmoid tumours (46 extra-abdominal, 21 abdominal, 13 intra-abdominal) were tested for oestrogen receptors alpha and beta, progesterone and androgen receptors, and somatostatin, in addition to HER2, cathepsin D, Ki-67, and c-KIT by immunohistochemistry.
  
  
  RESULTS
  All samples were negative for oestrogen receptor alpha, HER2, and the progesterone receptor. Positive staining for the androgen receptor was found in six extra-abdominal cases. Staining for oestrogen receptor beta was positive in four extra-abdominal, two abdominal, and one intra-abdominal case. Staining for somatostatin was positive in six extra-abdominal, two abdominal, and one intra-abdominal case, and staining for cathepsin D was positive in all cases. Positive staining for Ki-67 was found in 14 extra-abdominal, three abdominal, and three intra-abdominal cases. C-KIT was detectable in one abdominal case only.
  
  
  CONCLUSIONS
  The data from this immunohistochemical study show that the published effects of antioestrogens and imatinib mesylate in the treatment of aggressive fibromatoses may not be attributable to oestrogen receptor alpha or c-KIT expression.
authors.affiliation: Department of Orthopaedic Surgery, Medical University Graz, Auenbruggerplatz 5, A-8036 Graz, Austria.
authors.forename: A
authors.initials: A
authors.lastname: Leithner
authors.forename: M
authors.initials: M
authors.lastname: Gapp
authors.forename: R
authors.initials: R
authors.lastname: Radl
authors.forename: A
authors.initials: A
authors.lastname: Pascher
authors.forename: P
authors.initials: P
authors.lastname: Krippl
authors.forename: K
authors.initials: K
authors.lastname: Leithner
authors.forename: R
authors.initials: R
authors.lastname: Windhager
authors.forename: A
authors.initials: A
authors.lastname: Beham
mesh_terms: D000008:Abdominal Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D002402:Cathepsin D / Q000032:analysis; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D005260:Female; D018222:Desmoid Tumors / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D019394:Ki-67 Antigen / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis; D019009:Proto-Oncogene Proteins c-kit / Q000032:analysis; D011944:Receptors, Androgen / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012983:Soft Tissue Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000473:pathology; D013004:Somatostatin / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D011944:Receptors, Androgen; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013004:Somatostatin; D019009:Proto-Oncogene Proteins c-kit; D002402:Cathepsin D